German group’s pharma business expected to generate most of its revenues from US after strategic shift
Europe must pay more for medicines, says Bayer
Recent Posts
- Campaign to curb cars in Berlin sparks uproar ahead of election
- Nelson Peltz’s bidding war highlights $25bn wave of asset manager consolidation
- Stagflation fears demolish confidence in UK housing
- Renters’ Rights Act brings big changes to UK property market
- 400% gains for AI stocks help drive Hong Kong IPOs to 5-year high
